Clinical Milestone Payments Sample Clauses
The Clinical Milestone Payments clause defines the terms under which payments are made based on the achievement of specific clinical development milestones. Typically, these milestones might include the successful completion of phases in clinical trials, regulatory submissions, or approvals. The clause outlines the timing, amount, and conditions for each payment, ensuring that financial rewards are tied to tangible progress in the clinical development process. Its core function is to align financial incentives with project advancement, thereby managing risk and encouraging timely achievement of key objectives.
Clinical Milestone Payments. In addition to paying the License Fee, and without limiting Section 5.02(d) below, PII shall pay RBX the following non-refundable, non-creditable additional amounts upon the first occurrence of the applicable event (individually a “Milestone Payment” and collectively the “Milestone Payments”):
Clinical Milestone Payments. In connection with the clinical Development of each Licensed Product against a Target, Novartis shall pay, or cause to be paid, to Alnylam the following payments upon the achievement of the milestone events set forth below:
Clinical Milestone Payments. SB shall pay to CADUS the following clinical milestone payments within thirty (30) days of the first occurrence of each event below with respect to each Product:
Clinical Milestone Payments. Collaborator shall make milestone payments to Affymax based on the first achievement of each milestone event in the Licensed Territory for the Product as set forth in this Section 8.2. Collaborator shall pay to Affymax the amounts set forth below within thirty (30) days after the first achievement of the corresponding milestone event. Each milestone payment by Collaborator to Affymax hereunder shall be payable [*] achieved by one or more Products. Each such payment shall be made by wire transfer of immediately available funds into the account set forth in Section 8.1 unless otherwise designated in writing by Affymax. Each such payment is nonrefundable and noncreditable against any other payments due hereunder. [*] [*] [*] [*] [*] [*] [*] [*] [*] [*] [*] [*] [*] [*] [*] [*] [*] [*] [*] [*] * **
Clinical Milestone Payments. Tasgen shall pay clinical milestone fees , as follows, to Genexine conditioned upon each Licensed Product below reaching the following clinical development milestones: GX-P2 ▇▇ ▇ ▇▇ ▇▇-▇▇ ▇▇▇▇▇ ▇ ▇ ▇▇-▇▇ ▇▇▇ 1 1 Notwithstanding the foregoing, if Tasgen pursue an Out-License of the out-of-PRC license in accordance with Article 2.12 while reserving the PRC license, provided that the clinical development milestones listed above are achieved in PRC, the clinical milestone payments shall be reduced to 10% of the total clinical milestone payments indicated above.
Clinical Milestone Payments. Tasgen shall pay clinical milestone fees , as follows, to Genexine conditioned upon each Licensed Product below reaching the following clinical development milestones: Licensed Product Indication Milestone A: Initiate P3 Trials Milestone B: approval of NDA GX-P2 ▇▇ ▇ ▇▇ ▇▇-▇▇ ▇▇▇▇▇ ▇ ▇ ▇▇-▇▇ ▇▇▇ 1 1 Notwithstanding the foregoing, if Tasgen pursue an Out-License of the out-of-PRC license in accordance with Article 2.12 while reserving the PRC license, provided that the clinical development milestones listed above are achieved in PRC, the clinical milestone payments shall be reduced to 10% of the total clinical milestone payments indicated above.
Clinical Milestone Payments. Collaborator shall make milestone payments to Affymax based on the first achievement of each milestone event in the Licensed Territory for the Product as set forth in this Section 8.2. Collaborator shall pay to Affymax the amounts set forth below within thirty (30) days after the first achievement of the corresponding milestone event. Each milestone payment by Collaborator to Affymax hereunder shall be payable [ * ] achieved by one or more Products. Each such payment shall be made by wire transfer of immediately available funds into the account set forth in Section 8.1 unless otherwise designated in writing by Affymax. Each such payment is nonrefundable and noncreditable against any other payments due hereunder. [ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended.
Clinical Milestone Payments